SCHEMBL17444768

SCHEMBL17444768

O=C(NCc1ccccc1Cl)C(=O)NCc1n[nH]c(=O)c2ccccc12

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ AR P10275 4/20 0.64
▸ BRD4 O60885 1/20 0.58
▸ TDP1 Q9NUW8 2/20 0.57
▸ KDM4E B2RXH2 2/20 0.52
▸ POLB P06746 2/20 0.52
▸ KMT2A Q03164 3/20 0.52
▸ LMNA P02545 3/20 0.52
▸ MEN1 O00255 2/20 0.50
▸ MAPT P10636 2/20 0.50
▸ HTT P42858 2/20 0.50
▸ ALDH1A1 P00352 1/20 0.50
▸ GAA P10253 1/20 0.50
▸ THRB P10828 1/20 0.50
▸ RECQL P46063 1/20 0.50
▸ BLM P54132 1/20 0.50
▸ GABRP O00591 1/20 0.49
▸ GABRD O14764 1/20 0.49
▸ GABRA1 P14867 1/20 0.49
▸ GABRB1 P18505 1/20 0.49
▸ GABRG2 P18507 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17444767 0.83 KDM4E (0.73) ARBRD4TDP1KDM4EPOLB
SCHEMBL17444766 0.79 KDM4E (0.60) ARBRD4TDP1KDM4EPOLB
SCHEMBL17444764 0.79 TDP1 (0.57) BRD4TDP1KDM4EPOLBKMT2A
SCHEMBL13858810 0.78 KDM4E (0.66) ARBRD4TDP1KDM4EPOLB
SCHEMBL6783793 0.78 BRD4 (0.53) BRD4TDP1KDM4EKMT2ALMNA
SCHEMBL4713932 0.77 SMN1; SMN2 (0.61) ARBRD4TDP1KDM4EPOLB
SCHEMBL17444769 0.77 KDM4E (0.57) ARBRD4TDP1KDM4EPOLB
SCHEMBL6340069 0.75 BRD4 (0.75) ARBRD4TDP1KDM4EPOLB
SCHEMBL17444762 0.74 SMN1; SMN2 (0.52) BRD4TDP1KDM4EPOLBKMT2A
SCHEMBL25375732 0.73 NPC1 (0.66) POLBKMT2ALMNAMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9797882-B2 Method of screening for a compound for inhibitory activity of FN14-tweak interaction THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2017-10-24 — — US disclosed
US-9797882-B2 Method of screening for a compound for inhibitory activity of FN14-tweak interaction THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2017-10-24 — — US disclosed
US-20160146784-A1 COMPOSITIONS AND METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE ACTIVITY AT A TWEAK BINDING SITE ON A CRD OF FN14 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 2016-05-26 — — US disclosed
US-20160146784-A1 COMPOSITIONS AND METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE ACTIVITY AT A TWEAK BINDING SITE ON A CRD OF FN14 THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE 2016-05-26 — — US disclosed
US-9238034-B2 FN14 antagonists and therapeutic uses thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-01-19 — — US disclosed
US-9238034-B2 FN14 antagonists and therapeutic uses thereof THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (US) 2016-01-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160146784-A1 COMPOSITIONS AND METHODS OF SCREENING FOR COMPOUNDS THAT MODULATE ACTIVITY AT A TWEAK BINDING SITE ON A CRD OF FN14 FN1, ST14, TNFRSF1A AR 3623/4885BRD4 2545/4885TDP1 3570/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback